Neurimmune and TVM Capital Life Science Announce the Initiation of AL-S Pharma's Phase 1 Study of AP-101 for the Treatment of ALS
In: PR Newswire, 2019-10-16
Zeitungsartikel
Zugriff:
SCHLIEREN, Switzerland, Oct. 16, 2019 /PRNewswire/ -- AL-S Pharma AG, a biotech company jointly founded and financed by Neurimmune and TVM Capital Life Science, announced today enrollment of the first [...]
Titel: |
Neurimmune and TVM Capital Life Science Announce the Initiation of AL-S Pharma's Phase 1 Study of AP-101 for the Treatment of ALS
|
---|---|
Zeitschrift: | PR Newswire, 2019-10-16 |
Veröffentlichung: | 2019 |
Medientyp: | Zeitungsartikel |
Schlagwort: |
|
Sonstiges: |
|